Spyre Therapeutics, Inc. (SYRE) Financials

SYRE

FY2025 annual

Revenue $0 YoY not available

Net Income -$155.2M +25.4% YoY

EPS (Diluted) Not reported for FY2025

Operating Cash Flow -$169.3M -7.5% YoY

Market Cap $7.9B as of Oct 12, 2026

Price / Sales n/m revenue is not positive, FY2025

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 7.2x on $1.1B equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 12, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 4, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the SYRE SEC filings page.

Spyre Therapeutics, Inc. (SYRE) reported $0 in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI SYRE FY2025 2026-10-04

Spyre remains a development-stage business, funding heavy research with outside capital while reported losses continue to translate into cash outflows.

In FY2025, operating cash flow was -$169.3M against a net loss of $155.2M, indicating that reported losses largely reflected cash economics rather than merely noncash accounting charges. The 13.3x current ratio and 0.1x debt-to-equity ratio describe a liquid, lightly leveraged balance sheet, but its strength is tied more to financing and accumulated cash than to operating self-funding.

The latest valid revenue figure was only $886K in FY2023, compared with $89.5M of research and development; FY2025 R&D reached $171.7M. That combination describes an investment-led development model, not a sales-funded operation.

FY2025 financing supplied $309.0M while operating activities consumed $169.3M, showing that capital formation—not operations—supported the balance-sheet expansion. The reported liquidity comparison was 53.6 months of the latest annual operating outflow, a period-end balance-sheet measure rather than evidence of operating cash generation.

Financial Health Signals

Financial health score not available

Spyre Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Safe

74.24

Spyre Therapeutics, Inc. scores 74.24, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($7.9B) relative to total liabilities ($62.5M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

2/7

Spyre Therapeutics, Inc. passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

Spyre Therapeutics, Inc. reported a net loss of $155.2M while operations used $169.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Net Income

-$36.2M

YoY+1.4%

QoQ+47.5%

Spyre Therapeutics, Inc. reported -$36.2M in net income in Q2 2026. This represents an increase of 1.4% from the same quarter a year earlier. Against the prior quarter it is up 47.5%.

Revenue

Not reported for Q2 2026.

EBITDA

Not reported for Q2 2026.

EPS (Diluted)

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$162.0M

YoY+98.4%

QoQ+66.7%

5Y CAGR+36.0%

10Y CAGR+8.7%

Spyre Therapeutics, Inc. held $162.0M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

88M

YoY+46.0%

QoQ+1.5%

5Y CAGR+12.4%

10Y CAGR+20.7%

Spyre Therapeutics, Inc. had 88M shares outstanding in Q2 2026. This represents an increase of 46.0% from the same quarter a year earlier. Against the prior quarter it is up 1.5%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-3.3%

YoY+4.8pp

QoQ+7.0pp

Spyre Therapeutics, Inc.'s ROE was -3.3% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 4.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 7.0 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$65.5M

YoY+63.2%

QoQ+8.4%

Spyre Therapeutics, Inc. invested $65.5M in research and development in Q2 2026. This represents an increase of 63.2% from the same quarter a year earlier. Against the prior quarter it is up 8.4%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

SYRE Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SYRE quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Revenue	N/A	$0	$0-100.0%	$886K-62.0%	$2.3M-87.6%	$18.7M	$0	$0-100.0%	$3.9M-25.3%	$5.2M+12.5%	$4.6M	N/A	N/A
R&D Expenses	N/A	$171.7M+5.4%	$162.8M+81.9%	$89.5M+52.8%	$58.6M+2.6%	$57.1M-4.3%	$59.6M-7.7%	$64.6M+75.9%	$36.7M+60.9%	$22.8M+25.8%	$18.1M+58.4%	$11.5M+67.7%	$6.8M
SG&A Expenses	N/A	$47.9M+4.7%	$45.8M+14.6%	$39.9M+40.0%	$28.5M+4.4%	$27.3M+25.1%	$21.8M+38.8%	$15.7M+24.6%	$12.6M+25.5%	$10.1M+20.0%	$8.4M+41.1%	$5.9M+186.7%	$2.1M
Operating Income	N/A	-$209.6M-0.5%	-$208.6M+13.9%	-$242.3M-185.8%	-$84.8M-29.1%	-$65.6M+19.4%	-$81.5M-1.4%	-$80.3M-76.7%	-$45.5M-64.3%	-$27.7M-26.3%	-$21.9M-93.6%	-$11.3M-27.1%	-$8.9M
EBITDA	N/A	-$209.6M-0.5%	-$208.6M+13.7%	-$241.6M-190.3%	-$83.2M-29.9%	-$64.1M+20.4%	-$80.5M-0.7%	-$79.9M-76.9%	-$45.2M-64.7%	-$27.4M-26.0%	-$21.8M-94.0%	-$11.2M-26.3%	-$8.9M
Income Tax	N/A	-$15K-129.4%	$51K+296.2%	-$26K+80.9%	-$136K-196.5%	$141K	$0	$0	$0	$0	$0	$0	$0
Net Income	N/A	-$155.2M+25.4%	-$208.0M+38.6%	-$338.8M-304.2%	-$83.8M-27.4%	-$65.8M+18.7%	-$80.9M-3.4%	-$78.3M-76.5%	-$44.3M-62.8%	-$27.2M-25.5%	-$21.7M-92.1%	-$11.3M-9.2%	-$10.3M
EPS (Basic)	N/A	N/A	N/A	$13.76+155.3%	-$24.86+0.6%	-$25.02-1546.1%	-$1.52	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	—	N/A	N/A	$13.76	-$24.86+0.6%	-$25.02	-$1.52	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	N/A	N/A	7M	3M+28.2%	3M	53M	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0
R&D Expenses	$65.5M+63.2%	$60.4M+45.1%	N/A	$45.2M+1.1%	$40.1M+23.0%	$41.6M+19.2%	N/A	$44.7M+81.4%
SG&A Expenses	$16.1M+36.9%	$15.2M+27.5%	N/A	$11.6M+9.3%	$11.8M+2.4%	$11.9M-7.0%	N/A	$10.6M+24.0%
Operating Income	-$41.6M+0.7%	-$45.6M+14.8%	N/A	-$56.9M-2.7%	-$41.9M+5.0%	-$53.6M-12.1%	N/A	-$55.4M-202.1%
EBITDA	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$55.4M-202.1%
Income Tax	$0	$0+100.0%	N/A	$0-100.0%	$0	-$15K-146.9%	N/A	$18K+500.0%
Net Income	-$36.2M+1.4%	-$69.0M-54.1%	N/A	-$11.2M+83.8%	-$36.7M+5.5%	-$44.8M-2.1%	N/A	-$69.0M-72.1%
EPS (Basic)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$1.06+23.3%
EPS (Diluted)	N/A	-$0.74	N/A	N/A	N/A	N/A	N/A	$1.06
Diluted Shares (Avg)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	51M

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.

SYRE Balance Sheet

SYRE quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Total Assets	$777.8M+27.8%	$608.5M+78.0%	$341.9M+380.5%	$71.1M-35.3%	$109.9M-32.0%	$161.6M+94.3%	$83.2M+7.0%	$77.7M+38.6%	$56.1M-16.4%	$67.1M+73.5%	$38.7M	N/A
Current Assets	$777.8M+27.8%	$608.5M+78.2%	$341.5M+448.6%	$62.3M-37.0%	$98.9M-34.0%	$149.8M+101.0%	$74.5M-2.8%	$76.7M+39.4%	$55.0M-17.2%	$66.4M+73.5%	$38.3M	N/A
Cash & Equivalents	$85.7M-4.1%	$89.4M-52.7%	$188.9M+441.8%	$34.9M+130.2%	$15.1M-83.2%	$90.1M+368.0%	$19.3M-14.3%	$22.5M+75.2%	$12.8M-73.2%	$47.7M+63.0%	$29.3M+1019.8%	$2.6M
Short-Term Investments	$670.8M+30.6%	$513.7M+241.6%	$150.4M+621.3%	$20.8M-73.3%	$78.0M+38.8%	$56.2M+6.6%	$52.7M+1.2%	$52.1M+38.9%	$37.5M+137.9%	$15.8M+318.1%	$3.8M	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$62.5M-31.0%	$90.7M-42.6%	$157.8M+657.4%	$20.8M-19.8%	$26.0M+19.3%	$21.8M-5.7%	$23.1M+124.1%	$10.3M+79.6%	$5.7M+40.1%	$4.1M-93.3%	$60.9M	N/A
Current Liabilities	$58.7M+8.6%	$54.1M+69.1%	$32.0M+118.2%	$14.7M-27.2%	$20.1M+22.5%	$16.4M-10.4%	$18.4M+79.3%	$10.2M+81.9%	$5.6M+42.0%	$4.0M+57.2%	$2.5M	N/A
Non-Current Liabilities	$3.9M-89.5%	$36.6M-70.9%	$125.9M+1935.7%	$6.2M+5.9%	$5.8M+9.3%	$5.3M+12.7%	$4.7M+6487.5%	$72K-35.1%	$111K-15.9%	$132K-99.8%	$58.3M	N/A
Total Equity	$715.2M+38.1%	$517.8M+181.4%	$184.0M+265.8%	$50.3M-40.1%	$83.9M-40.0%	$139.8M+132.7%	$60.1M-10.9%	$67.4M+34.0%	$50.3M-20.1%	$63.0M+383.5%	-$22.2M-93.6%	-$11.5M
Retained Earnings	-$1.1B-16.0%	-$972.4M-27.2%	-$764.4M-79.6%	-$425.6M-24.5%	-$341.8M-23.8%	-$276.0M-41.5%	-$195.1M-67.0%	-$116.9M-61.2%	-$72.5M-60.2%	-$45.3M-92.0%	-$23.6M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$1.2B+117.7%	$764.0M+34.1%	$777.8M+27.8%	$504.6M+19.8%	$538.8M+23.6%	$569.8M+16.9%	$608.5M+78.0%	$421.1M+103.2%
Current Assets	$1.2B+117.7%	$764.0M+34.1%	$777.8M+27.8%	$504.6M+19.8%	$538.8M+23.7%	$569.8M+16.9%	$608.5M+78.2%	$421.1M+104.5%
Cash & Equivalents	$162.0M+98.4%	$97.2M+100.4%	$85.7M-4.1%	$64.9M-9.3%	$81.7M+80.9%	$48.5M-78.7%	$89.4M-52.7%	$71.6M-21.0%
Short-Term Investments	$983.3M+121.0%	$644.3M+24.8%	$670.8M+30.6%	$421.3M+23.0%	$444.9M+16.8%	$516.3M+100.8%	$513.7M+241.6%	$342.6M+203.2%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$71.9M-13.5%	$93.1M+6.9%	$62.5M-31.0%	$49.5M-47.2%	$83.1M+34.7%	$87.2M-74.0%	$90.7M-42.6%	$93.7M-79.3%
Current Liabilities	$63.3M-23.8%	$85.2M+20.5%	$58.7M+8.6%	$46.3M-19.6%	$83.1M+275.5%	$70.7M+65.1%	$54.1M+69.1%	$57.5M+28.2%
Non-Current Liabilities	$8.6M	$8.0M-51.6%	$3.9M-89.5%	$3.2M-91.1%	$0-100.0%	$16.5M-94.4%	$36.6M-70.9%	$36.2M-91.1%
Total Equity	$1.1B+141.6%	$670.8M+39.0%	$715.2M+38.1%	$455.1M+39.0%	$455.8M+21.7%	$482.6M+216.9%	$517.8M+181.4%	$327.4M+233.4%
Retained Earnings	-$1.2B-17.0%	-$1.2B-17.6%	-$1.1B-16.0%	-$1.1B-16.3%	-$1.1B-24.4%	-$1.0B-25.8%	-$972.4M-27.2%	-$916.1M-30.6%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

SYRE Cash Flow Statement

SYRE quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Operating Cash Flow	-$208.9M	-$169.3M-7.5%	-$157.4M-57.6%	-$99.9M-24.7%	-$80.1M-49.2%	-$53.7M+29.1%	-$75.8M-15.3%	-$65.7M-104.1%	-$32.2M-30.8%	-$24.6M-30.7%	-$18.8M-71.6%	-$11.0M-49.7%	-$7.3M
Depreciation & Amortization	N/A	$0	$0-100.0%	$744K-52.5%	$1.6M-0.6%	$1.6M+58.2%	$996K+138.3%	$418K+42.7%	$293K+17.7%	$249K+88.6%	$132K+48.3%	$89K+368.4%	$19K
Stock-Based Compensation	N/A	$37.6M-16.1%	$44.8M+74.6%	$25.7M+261.1%	$7.1M-11.5%	$8.0M+28.5%	$6.3M+28.3%	$4.9M+13.9%	$4.3M+71.7%	$2.5M+104.1%	$1.2M+59.2%	$767K+421.8%	$147K
Capital Expenditures	N/A	N/A	$0	$0-100.0%	$38K-93.4%	$573K-86.6%	$4.3M+186.9%	$1.5M+253.6%	$422K-31.8%	$619K+192.0%	$212K+1.9%	$208K+14.9%	$181K
Free Cash Flow	N/A	N/A	-$157.4M-57.6%	-$99.9M-24.6%	-$80.2M-47.7%	-$54.3M+32.2%	-$80.1M-19.2%	-$67.2M-106.0%	-$32.6M-29.3%	-$25.2M-32.4%	-$19.1M-70.3%	-$11.2M-48.9%	-$7.5M
Investing Cash Flow	-$463.7M	-$143.5M+59.4%	-$353.3M-225.9%	-$108.4M-290.1%	$57.0M+352.0%	-$22.6M-197.5%	-$7.6M-337.3%	-$1.7M+88.6%	-$15.2M+32.4%	-$22.5M-86.6%	-$12.1M	N/A	N/A
Financing Cash Flow	$753.0M	$309.0M-24.8%	$410.9M+13.8%	$361.1M+746.0%	$42.7M+2963.7%	$1.4M-99.1%	$154.5M+135.1%	$65.7M+15.2%	$57.1M+367.3%	$12.2M-75.3%	$49.4M	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$69.9M-50.1%	-$57.4M-40.0%	-$44.6M-19.8%	-$37.1M-26.2%	-$46.6M+25.2%	-$41.0M-43.6%	-$37.2M-19.9%	-$29.4M+15.0%
Depreciation & Amortization	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0
Stock-Based Compensation	$13.5M+44.1%	$12.8M+44.6%	N/A	$9.6M-27.0%	$9.4M+7.8%	$8.9M-36.0%	N/A	$13.1M+172.9%
Investing Cash Flow	-$297.9M-477.1%	$56.6M+92855.7%	-$247.4M-45.1%	$25.0M-41.5%	$79.0M+165.5%	-$61K+99.9%	-$170.5M-383.5%	$42.7M+143.8%
Financing Cash Flow	$432.6M+59079.6%	$12.3M+9704.0%	$312.8M+38.7%	-$4.6M-136.3%	$731K+103.1%	$125K-99.9%	$225.6M+37.9%	$12.8M+202.0%

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

SYRE Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SYRE quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Operating Margin	N/A	N/A	-27348.0%	-3640.2%	-350.3%	N/A	N/A	-1169.3%	-531.7%	-473.3%	N/A	N/A
Net Margin	N/A	N/A	-38238.2%	-3598.7%	-351.1%	N/A	N/A	-1140.6%	-523.3%	-468.8%	N/A	N/A
Return on Equity	-21.7%+18.5pp	-40.2%+143.9pp	-184.1%-17.5pp	-166.6%-88.2pp	-78.4%-20.5pp	-57.9%+72.4pp	-130.3%-64.5pp	-65.8%-11.7pp	-54.1%-19.7pp	-34.5%	N/A	N/A
Return on Assets	-20.0%+14.2pp	-34.2%+64.9pp	-99.1%+18.7pp	-117.8%-57.9pp	-59.9%-9.8pp	-50.0%+44.0pp	-94.1%-37.0pp	-57.0%-8.5pp	-48.6%-16.2pp	-32.4%-3.1pp	-29.2%	N/A
Current Ratio	13.25+2.0x	11.26+0.6x	10.68+6.4x	4.25-0.7x	4.91-4.2x	9.11+5.1x	4.06-3.4x	7.49-2.3x	9.77-7.0x	16.75+1.6x	15.17	N/A
Debt-to-Equity	0.09-0.1x	0.18-0.7x	0.86+0.4x	0.41+0.1x	0.31+0.2x	0.16-0.2x	0.38+0.2x	0.150.0x	0.110.0x	0.07	N/A	N/A
Asset Turnover	0.000.0x	0.000.0x	0.000.0x	0.03-0.1x	0.17+0.2x	0.000.0x	0.00-0.1x	0.050.0x	0.090.0x	0.07	N/A	N/A
FCF Margin	N/A	N/A	-11276.5%	-3442.8%	-289.7%	N/A	N/A	-838.9%	-484.8%	-411.7%	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-3.3%+4.8pp	-10.3%-1.0pp	N/A	-2.5%+18.6pp	-8.1%+2.3pp	-9.3%+19.5pp	N/A	-21.1%
Return on Assets	-3.1%+3.7pp	-9.0%-1.2pp	N/A	-2.2%+14.2pp	-6.8%+2.1pp	-7.9%+1.1pp	N/A	-16.4%+3.0pp
Current Ratio	18.53+12.0x	8.97+0.9x	13.25+2.0x	10.90+3.6x	6.49-13.2x	8.06-3.3x	11.26+0.6x	7.32+2.7x
Debt-to-Equity	0.07-0.1x	0.140.0x	0.09-0.1x	0.11-0.2x	0.180.0x	0.18-2.0x	0.18-0.7x	0.29
Asset Turnover	N/A	N/A	N/A	N/A	N/A	N/A	N/A	0.000.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Spyre Therapeutics, Inc. SYRE	FY2025	$0	-$155.2M	N/A	$7.9B	—
Upstream Bio, Inc. UPB	FY2025	$2.9M	-$143.4M	N/A	$257.4M	54/100
Arbutus Biopharma Corporation ABUS	FY2025	$14.1M	-$33.5M	N/A	$836.0M	63/100
UroGen Pharma Ltd. URGN	FY2025	$109.8M	-$153.5M	N/A	$1.8B	42/100
Rapport Therapeutics, Inc. RAPP	FY2025	N/A	-$111.5M	N/A	$1.5B	—

Where Spyre Therapeutics, Inc. Ranks

Frequently Asked Questions

What is Spyre Therapeutics, Inc.'s annual revenue?

Spyre Therapeutics, Inc. (SYRE) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Spyre Therapeutics, Inc. profitable?

No, Spyre Therapeutics, Inc. (SYRE) reported a net income of -$155.2M in fiscal year 2025.

What is Spyre Therapeutics, Inc.'s EBITDA?

Spyre Therapeutics, Inc. (SYRE) had EBITDA of -$209.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Spyre Therapeutics, Inc.'s return on equity (ROE)?

Spyre Therapeutics, Inc. (SYRE) has a return on equity of -21.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Spyre Therapeutics, Inc.'s operating cash flow?

Spyre Therapeutics, Inc. (SYRE) recorded an outflow of $169.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Spyre Therapeutics, Inc.'s total assets?

Spyre Therapeutics, Inc. (SYRE) had $777.8M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Spyre Therapeutics, Inc. spend on research and development?

Spyre Therapeutics, Inc. (SYRE) invested $171.7M in research and development during fiscal year 2025.

How many shares does Spyre Therapeutics, Inc. have outstanding?

Spyre Therapeutics, Inc. (SYRE) had 79M shares outstanding as of fiscal year 2025.

What is Spyre Therapeutics, Inc.'s current ratio?

Spyre Therapeutics, Inc. (SYRE) had a current ratio of 13.25 as of fiscal year 2025, which is generally considered healthy.

What is Spyre Therapeutics, Inc.'s debt-to-equity ratio?

Spyre Therapeutics, Inc. (SYRE) had a debt-to-equity ratio of 0.09 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Spyre Therapeutics, Inc.'s return on assets (ROA)?

Spyre Therapeutics, Inc. (SYRE) had a return on assets of -20.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Spyre Therapeutics, Inc.'s P/E ratio?

Spyre Therapeutics, Inc. (SYRE) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $7.9B as of Oct 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Spyre Therapeutics, Inc.'s price-to-sales ratio?

Spyre Therapeutics, Inc. (SYRE) has no price-to-sales ratio at the moment: revenue is not positive (FY2025). The market capitalization is $7.9B as of Oct 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Spyre Therapeutics, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Spyre Therapeutics, Inc. (SYRE) held $756.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $169.3M over that year. Dividing the one by the other, the reported balance equals about 54 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Spyre Therapeutics, Inc.'s Altman Z-Score?

Spyre Therapeutics, Inc. (SYRE) has an Altman Z-Score of 74.24, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Spyre Therapeutics, Inc.'s Piotroski F-Score?

Spyre Therapeutics, Inc. (SYRE) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Spyre Therapeutics, Inc.'s earnings high quality?

Spyre Therapeutics, Inc. (SYRE) reported a net loss of $155.2M while operations used $169.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.